Semaglutide's Promising Impact on Heart Failure and Obesity
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on October 6th, 2023
|
Obesity is a contributing factor in the onset and progression of heart failure, exacerbating its symptoms and diminishing the overall quality of life. Semaglutide, a medication originally approved for diabetes management known to induce substantial weight loss, was the subject of a study aiming to investigate whether it could improve clinical outcomes for obese patients with heart failure.
This study involved 529 participants diagnosed with heart failure, characterized by a left ventricular ejection fraction of over 45%. The average body mass index (BMI) in this cohort was 37, with 15% of them having been previously hospitalized due to heart failure complications. The Kansas City Cardiomyopathy Questionnaire (KCCQ) was employed to assess their health status. These participants were randomly divided into two groups, one receiving a subcutaneous injection of a placebo and the other receiving 2.4 mg of semaglutide once weekly. Following 52 weeks of treatment, the research findings indicated that semaglutide significantly reduced participants' body weight, improved their physical exercise capacity, and enhanced their KCCQ scores. Specifically, the semaglutide group experienced a 13% reduction in body weight and could walk 21 meters within 6 minutes, while the placebo group only had a 2% reduction in body weight and their 6-minute walk distance was only 1.2 meter. Additionally, blood work revealed that semaglutide led to a reduction in inflammation, evidenced by a significant decrease in C-reactive protein levels. Furthermore, semaglutide was well-tolerated, with fewer serious adverse events reported in the semaglutide group compared to the placebo group.
This study involved 529 participants diagnosed with heart failure, characterized by a left ventricular ejection fraction of over 45%. The average body mass index (BMI) in this cohort was 37, with 15% of them having been previously hospitalized due to heart failure complications. The Kansas City Cardiomyopathy Questionnaire (KCCQ) was employed to assess their health status. These participants were randomly divided into two groups, one receiving a subcutaneous injection of a placebo and the other receiving 2.4 mg of semaglutide once weekly. Following 52 weeks of treatment, the research findings indicated that semaglutide significantly reduced participants' body weight, improved their physical exercise capacity, and enhanced their KCCQ scores. Specifically, the semaglutide group experienced a 13% reduction in body weight and could walk 21 meters within 6 minutes, while the placebo group only had a 2% reduction in body weight and their 6-minute walk distance was only 1.2 meter. Additionally, blood work revealed that semaglutide led to a reduction in inflammation, evidenced by a significant decrease in C-reactive protein levels. Furthermore, semaglutide was well-tolerated, with fewer serious adverse events reported in the semaglutide group compared to the placebo group.